Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry

Hazar, Volkan; Kesik, Vural; Karasu, Gülsün; Öztürk, Gülyüz; Küpesiz, Alphan; Kılıç, Suar Çakı; Ataş, Erman; Uygun, Vedat; Eker, Nurşah; Erbey, Fatih; Bengoa, Şebnem Yılmaz; Emir, Suna; Anak, Sema; Öniz, Haldun; Daloğlu, Hayriye; Aksoylar, Serap; Koçak, Ülker; Karakükçü, Musa; Elli, Murat; Kurucu, Nilgün; Yeşilipek, Akif

doi:10.1080/10428194.2017.1330472

Cited by 5 publications

(6 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hazar et al evaluated 21 patients with LBL (5 and 16 patients with B-LBL and T-LBL, respectively) undergoing HSCT. Among them, 16 patients received allo-HSCT, while 5 patients received auto-HSCT, and the overall OS and EFS were 48% and 44%, respectively (36). In a retrospective multicenter study of the largest series of LBL patients treated with auto-HSCT or MSD-HSCT, MSD-HSCT was associated with fewer relapses than was auto-HSCT (5-year rate, 34% vs. 56%; P=0.004) but was also associated with higher TRM (6-month rate, 18% vs. 3%; P=0.002), which obscured any potential survival benefit (22).…”

Section: Discussionmentioning

confidence: 99%

Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma

Li,

Zhang,

Fan

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundHematopoietic stem cell transplantation (HSCT) is an important treatment for T-cell lymphoblastic lymphoma/leukemia (T-LBL). To compare the efficacy and influencing factors of autologous hematopoietic stem cell transplantation (auto-HSCT) with those of allogeneic hematopoietic stem cell transplantation (allo-HSCT) from different donors for the treatment of T-cell lymphoblastic lymphoma/leukemia (T-LBL) and provide a basis for selection of appropriate transplant methods and donors.MethodsTo provide evidence of appropriate transplant methods for these patients, we retrospectively summarized the clinical characteristics of 75 T-LBL patients receiving HSCT at Henan Cancer Hospital between March 2012 and October 2021. Overall survival (OS), progression-free survival (PFS), cumulative incidence of relapse (CIR), non-relapse mortality (NRM), and related factors affecting efficacy were analyzed.ResultsThe 3-year CIR (39.9% vs 31.1%, P=0.745), 3-year PFS (60.1% vs 49.6%, P=0.434), and 3-year OS (62.8% vs 53.0%, P=0.450) were not significantly different between the auto-HSCT and allo-HSCT groups. However, the 3-year NRM was significantly higher in the allo-HSCT group (0% vs 27.2%, P=0.033). Multivariate analysis showed that the first complete remission (CR1) after HSCT was an independent influencing factor of higher OS (HR=2.498, P=0.029) and PFS (HR=2.576, P=0.016). The absence of mediastinal invasion in patients receiving HSCT was an independent influencing factor of better PFS (HR=2.977, P=0.029) and lower CIR (HR=4.040, P=0.027). With respect to the impact of donor source, the NRM in the unrelated donor (URD) and haploid donor (HPD) groups was significantly higher than that in the auto-HSCT group (P=0.021 and P=0.003, respectively), while there was no significant difference between matched sibling donors (MSD) and auto-HSCT. Compared with the MSD-HSCT group, the auto-HSCT group showed an increasing trend in 3-year CIR (39.9 ± 11.1% vs 32.6 ± 11.2%, P=0.697) and a lower trend in 3-year OS (62.8 ± 11.4% vs 64.4 ± 12.2%, P=0.929).ConclusionsHSCT is an effective consolidation treatment option for patients with T-LBL without mediastinal invasion and with CR1 before transplantation. For CR1 patients, auto-HSCT and MSD-HSCT are effective modalities for improving survival. In non-CR1 patients without an MSD, matched unrelated donors and haploidentical donor transplantations are the best treatment options to reduce relapse and improve prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma

Li,

Zhang,

Fan

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…However, Qi et al used the Cox proportional hazard to assess bleeding's independent prognostic value and fine-gray competing risk models for survival analyses, lasso regression to select a training set to derive the bleeding score, and logistic regression to derive the value-added score. There was an increased cumulative incidence of overall mortality (HR = 10:90), 11 Computational and Mathematical Methods in Medicine nonrelapse mortality (HR = 14:84), and combined endpoints (HR = 9:30), but not the cumulative incidence of relapse in higher bleeding class HSCT patients [58]. The performance comparison of our methodology with some of these stateof-the-art ones is provided in Table 6.…”

Section: Discussionmentioning

confidence: 99%

Survival Prediction of Children Undergoing Hematopoietic Stem Cell Transplantation Using Different Machine Learning Classifiers by Performing Chi-Square Test and Hyperparameter Optimization: A Retrospective Analysis

Ratul

Habiba

Nishat

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Bone marrow transplant (BMT) is an effective surgical treatment for bone marrow-related disorders. However, several associated risk factors can impair long-term survival after BMT. Machine learning (ML) technologies have been proven useful in survival prediction of BMT receivers along with the influences that limit their resilience. In this study, an efficient classification model predicting the survival of children undergoing BMT is presented using a public dataset. Several supervised ML methods were investigated in this regard with an 80-20 train-test split ratio. To ensure prediction with minimal time and resources, only the top 11 out of the 59 dataset features were considered using Chi-square feature selection method. Furthermore, hyperparameter optimization (HPO) using the grid search cross-validation (GSCV) technique was adopted to increase the accuracy of prediction. Four experiments were conducted utilizing a combination of default and optimized hyperparameters on the original and reduced datasets. Our investigation revealed that the top 11 features of HPO had the same prediction accuracy (94.73%) as the entire dataset with default parameters, however, requiring minimal time and resources. Hence, the proposed approach may aid in the development of a computer-aided diagnostic system with satisfactory accuracy and minimal computation time by utilizing medical data records.

show abstract

“…The majority of data are limited to retrospective analyses. These studies are heterogeneous, including series of selected patients submitted to transplant (Loiseau et al , 1991; Bureo et al , 1995; Won et al , 2006; Giulino‐Roth et al , 2013), series of patients derived from transplant registries (Ladenstein et al , 1997; Gross et al , 2010; Hazar et al , 2018), or series of patients relapsed from multicentre protocols (Philip et al , 1993; Jourdain et al , 2015; Rigaud et al , 2019). The conditioning regimens are also heterogeneous.…”

Section: Haematopoietic Stem Cell Transplantmentioning

confidence: 99%

“…Multivariate analysis showed a higher risk of treatment failure for patients who were not transplanted in CR ( P < 0·01), regardless of the donor type. Hazar et al (2018) reported data from the Turkish paediatric bone marrow transplantation registry on 62 r/r NHL patients transplanted between 2006 and 2014. For the 22 B‐NHL, the OS rate was 68%; patients with chemoresistant disease at HSCT had a significantly lower OS rate than those with a chemosensitive disease (81% vs. 33%, P < 0·001).…”

Section: Haematopoietic Stem Cell Transplantmentioning

confidence: 99%

Treatment of relapsed/refractory paediatric aggressive B‐cell non‐Hodgkin lymphoma

2020

View full text Add to dashboard Cite

Summary Aggressive B‐cell non‐Hodgkin lymphoma (B‐NHL) accounts for ≈60% of NHL in children/adolescents. In newly diagnosed Burkitt lymphoma and diffuse large B‐cell lymphoma, short intensive multiagent chemotherapy is associated with a five‐year event‐free survival of around 90%. Very few children/adolescents with aggressive B‐NHL show a relapsed/refractory (r/r) disease. The outcome is poor, with cure rates <30%, and there is no standard of care. Rituximab‐containing salvage regimens may provide a complete/partial response in 60–70% of cases. However, long‐term survival is <10% for non‐transplanted patients. Autologous or allogeneic haematopoietic stem cell transplant is, nowadays, the best option for responding patients, with survival rates around 50%. The benefit of autologous versus allogeneic HSCT is not clear. Numerous novel therapies for r/r B‐NHL are currently being tested in adults, including next‐generation monoclonal antibodies, novel cellular therapy strategies and therapies directed against new targets. Some are under investigation also in children/adolescents, with promising preliminary results.

show abstract

Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry

Cited by 5 publications

References 31 publications

Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma

Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma

Survival Prediction of Children Undergoing Hematopoietic Stem Cell Transplantation Using Different Machine Learning Classifiers by Performing Chi-Square Test and Hyperparameter Optimization: A Retrospective Analysis

Treatment of relapsed/refractory paediatric aggressive B‐cell non‐Hodgkin lymphoma

Contact Info

Product

Resources

About